Immunic Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedMarch 31, 2026orTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromtoCommission File Number:001-36201Immunic, Inc.(Exact name of registrant as specified in its charter) 56-2358443 (332) 255-9818(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading symbol(s)Name of each exchange on whichregisteredCommon Stock, $0.0001 par valueIMUXThe Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filingrequirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and postsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smallerreportingcompany☒Emerging growth company☐ Largeacceleratedfiler☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). On April 30, 2026, 13,621,526 shares of common stock, $0.0001 par value, were outstanding. IMMUNIC, INC.INDEX PART I - FINANCIAL INFORMATION Item1.Condensed Consolidated Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of OperationsCondensed Consolidated Statements of Comprehensive LossCondensed Consolidated Statements of Stockholders’ Equity(Deficit)Condensed Consolidated Statements of Cash FlowsNotes to Condensed Consolidated Financial StatementsItem2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem3.Quantitative and Qualitative Disclosures About Market RiskItem4.Controls and Procedures Item1.Legal ProceedingsItem1A.Risk FactorsItem2.Unregistered Sales of Equity Securitiesand Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem4.Mine Safety DisclosuresItem5.Other InformationItem6.Exhibits EXPLANATORY NOTE Reverse Stock Split On April 14, 2026, we held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, our stockholders votedto authorize our Board of Directors (the “Board”), in its discretion, to amend our certificate of incorporation, as amended and restated, toeffect a reverse stock split of all of the outstanding shares of the Common Stock, at a ratio in the range of 1-for-10 to 1-for-30, with suchratio to be determined by the Board. Following the Special Meeting, the Board approved a reverse stock split of our issued and outstandingCommon Stock, at a ratio of 1-for-10, which became effective April 27, 2026.All share information in this Quarterly Report on Form 10-Qhas been restated for all years and periods presented for the impact of the 1-for-10 reverse stock split. IMMUNIC, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) IMMUNIC, INC. Condensed Consolidated Statements of Operations (Inthousands,exceptshareandpershareamounts)(Unaudited) IMMUNIC, INC. Condensed Consolidated Statements of Comprehensive Loss (Inthousands)(Unaudited) Three MonthsEnded March 31, The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. IMMUNIC, INC. Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Inthousands,exceptshares)(Unaudited)Three Months Ended March 31, 2026 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. IMMUNIC, INC. Condensed Consolidated Statements of Cash Flows (Inthousands)(Unaudited) IMMUNIC, INC. Notes to Condensed Consolidated Financial Statements(Unaudited) 1. Description of Business and Basis of Financial Statements Description of Business Immunic, Inc. ("Immunic" or the "Company") is a late-stage biotechnology company pioneering the development of novel oraltherapies for neur